# Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

> **NCT00193037** · PHASE2 · COMPLETED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 102 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Liposomal Doxorubicin
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00193037
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2008-12
- **Final completion:** 2009-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2013-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00193037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00193037, "Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00193037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*